Exploring nurses' experiences of a tailored intervention to increase MMR vaccine acceptance in a Somali community in Stockholm, Sweden: a qualitative interview study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 02 2023
Historique:
entrez: 6 2 2023
pubmed: 7 2 2023
medline: 9 2 2023
Statut: epublish

Résumé

To explore nurses' experiences of a tailored intervention that supported them with knowledge and tools to use during encounters and dialogue with parents with low vaccine acceptance. A qualitative study with in-depth interviews conducted in 2017. Data were analysed using thematic analysis. This study was part of a multicomponent intervention targeting Somali parents and the nurses at child health centres in the Rinkeby and Tensta neighbourhoods of Stockholm. An area with documented low measles, mumps and rubella (MMR) vaccination coverage. Previous research has revealed that Somali parents in the community delayed MMR vaccination due to fear of autism despite lack of scientific evidence. The interventions were implemented in 2015-2017. Eleven nurses employed at the child health centres involved in the intervention participated in interviews. The tailored intervention targeting nurses included a series of seminars, a narrative film and an information card with key messages for distribution to parents. The qualitative analysis revealed an overarching theme: perception of improved communication with parents. Two underlying themes were identified: (1) feeling more confident to address parents' MMR vaccine concerns and (2) diverse tools as useful support to dispel myth and reduce language barriers. From the nurses' perspective, the tailored intervention was useful to improve communication with parents having vaccine concerns. Nurses have a crucial role in vaccine uptake and acceptance. Interventions aiming to strengthen their communication with parents are therefore essential, especially in areas with lower vaccine acceptance.

Identifiants

pubmed: 36746543
pii: bmjopen-2022-067169
doi: 10.1136/bmjopen-2022-067169
pmc: PMC9906253
doi:

Substances chimiques

Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e067169

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Pediatrics. 2008 Oct;122(4):718-25
pubmed: 18829793
N Engl J Med. 2002 Nov 7;347(19):1477-82
pubmed: 12421889
J Pediatr. 2016 Oct;177S:S187-S202
pubmed: 27666267
Vaccine. 2018 Oct 22;36(44):6480-6490
pubmed: 29395532
Vaccine. 2015 Aug 14;33(34):4176-9
pubmed: 25896376
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
Pediatrics. 2008 Jul;122(1):149-53
pubmed: 18595998
Vaccine. 2014 Nov 28;32(50):6752-7
pubmed: 25454859
Pediatric Health Med Ther. 2019 Dec 18;10:177-182
pubmed: 31908567
Lancet. 1998 Feb 28;351(9103):637-41
pubmed: 9500320
Vaccine. 2016 Sep 22;34(41):5013-5020
pubmed: 27576074
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Int J Environ Res Public Health. 2018 Nov 01;15(11):
pubmed: 30388799
Euro Surveill. 2012 Jun 28;17(26):
pubmed: 22790533
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
Acad Pediatr. 2013 Sep-Oct;13(5):481-8
pubmed: 24011751
Minn Med. 2015 Oct;98(10):33-6
pubmed: 26596077
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):32-39
pubmed: 31802154
Public Health. 2019 Jun;171:97-105
pubmed: 31121558
Vaccine. 2014 Jun 17;32(29):3623-9
pubmed: 24814559
BMC Pediatr. 2012 Sep 21;12:154
pubmed: 22998654
Pediatrics. 2014 Jul;134(1):e220-8
pubmed: 24913790
Public Health Pract (Oxf). 2022 Aug 05;4:100305
pubmed: 36570400
Cochrane Database Syst Rev. 2017 Feb 07;2:CD011787
pubmed: 28169420
Euro Surveill. 2019 Jan;24(2):
pubmed: 30646979
Expert Rev Vaccines. 2018 Nov;17(11):989-1004
pubmed: 30359151
Clin Microbiol Infect. 2017 May;23(5):279-280
pubmed: 27851999

Auteurs

Emma Appelqvist (E)

Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden emma.appelqvist@folkhalsomyndigheten.se.
Department of Clinical Microbiology, Department of Translational Medicine, Lund University, Lund, Sweden.

Asha Jama (A)

Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden.
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Asli Kulane (A)

Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Adam Roth (A)

Department of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden.
Department of Clinical Microbiology, Department of Translational Medicine, Lund University, Lund, Sweden.

Ann Lindstrand (A)

Department of Immunization, Vaccines and Biologicals, Unit Essential Programme on Immunization, WHO, Geneve, Switzerland.

Karina Godoy-Ramirez (K)

The Office of the Head for Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH